Dyne Therapeutics reports preliminary cash of ~$1.1B as of Dec 31, 2025

Dyne Therapeutics, Inc.

Preliminary unaudited cash, cash equivalents and marketable securities of approximately $1.1 billion as of December 31, 2025.
Figure is a management estimate subject to completion of financial closing procedures; no audit or review by independent accountants.
Company also presented at J.P. Morgan Healthcare Conference on January 12, 2026; presentation content was not detailed in this filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.